Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3781695 | 0.91 | P2RX3 (0.64) | P2RX3P2RX2 | |
| SCHEMBL13014890 | 0.88 | — | — | |
| SCHEMBL3781743 | 0.81 | P2RX3 (0.53) | P2RX3P2RX2 | |
| SCHEMBL3770245 | 0.80 | P2RX3 (0.48) | P2RX3P2RX2 | |
| SCHEMBL3659395 | 0.80 | P2RX3 (0.54) | P2RX3P2RX2 | |
| SCHEMBL13014894 | 0.80 | P2RX3 (0.50) | P2RX3P2RX2 | |
| SCHEMBL4165101 | 0.78 | P2RX3 (0.54) | P2RX3P2RX2 | |
| SCHEMBL2272754 | 0.77 | P2RX3 (0.51) | P2RX3P2RX2 | |
| SCHEMBL2274055 | 0.77 | P2RX3 (0.54) | P2RX3P2RX2 | |
| SCHEMBL4150982 | 0.76 | P2RX3 (0.55) | P2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150080408-A1 | PYRIDINYL AMIDES AS P2X3 AND P2X2/3 INHIBITORS | ROCHE PALO ALTO LLC (US) | 2015-03-19 | — | — | US | claimed |
| US-8895589-B2 | Pyridinyl amides as P2X3 and P2X2/3 inhibitors | ROCHE PALO ALTO LLC (US) | 2014-11-25 | — | — | US | claimed |
| US-20130165443-A1 | BIPHENYL AND PHENYL-PYRIDINE AMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | BROKA CHRIS ALLEN (US) | 2013-06-27 | — | — | US | claimed |
| US-20100324056-A1 | BIPHENYL AND PHENYL-PYRIDINE AMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | BROKA CHRIS ALLEN | 2010-12-23 | — | — | US | claimed |
| US-20170057932-A1 | BIPHENYL AND PHENYL-PYRIDINE AMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-03-02 | — | — | US | disclosed |
| US-9505726-B2 | Substituted biphenyl amides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150080408-A1 | PYRIDINYL AMIDES AS P2X3 AND P2X2/3 INHIBITORS | ROCHE PALO ALTO LLC (US) | 2015-03-19 | — | — | US | disclosed |
| US-8895589-B2 | Pyridinyl amides as P2X3 and P2X2/3 inhibitors | ROCHE PALO ALTO LLC (US) | 2014-11-25 | — | — | US | disclosed |
| US-20130165443-A1 | BIPHENYL AND PHENYL-PYRIDINE AMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | BROKA CHRIS ALLEN (US) | 2013-06-27 | — | — | US | disclosed |
| US-8283383-B2 | Biphenyl amides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2012-10-09 | — | — | US | disclosed |
| US-20100324056-A1 | BIPHENYL AND PHENYL-PYRIDINE AMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | BROKA CHRIS ALLEN | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080408-A1 | PYRIDINYL AMIDES AS P2X3 AND P2X2/3 INHIBITORS | P2RX3, P2RX2, P2RX1 | P2RX3 1/4885P2RX2 2/4885 |
| US-20100324056-A1 | BIPHENYL AND PHENYL-PYRIDINE AMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX7 | P2RX3 1/4885P2RX2 2/4885 |
| US-20170057932-A1 | BIPHENYL AND PHENYL-PYRIDINE AMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX7 | P2RX3 1/4885P2RX2 2/4885 |
| US-20130165443-A1 | BIPHENYL AND PHENYL-PYRIDINE AMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX7 | P2RX3 1/4885P2RX2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.